HCW Biologics Inc (HCWB)
HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for chronic, low-grade inflammation and age-related diseases. The company’s pipeline includes HCW9218, a bifunctional molecule that has completed Phase 1 studies in chemotherapy-refractory solid tumors and Phase 1b/2 testing in pancreatic cancer, as well as HCW9302, an injectable IL-2 fusion protein complex in Phase 1 for autoimmune and proinflammatory conditions, including alopecia areata. Other development programs include HCW9201 and HCW9206 for memory-like natural killer cells, cancer, and pathogens, along with HCW11-006, HCW11-002, HCW11-0027, and HCW11-018, which are being studied across oncology and related indications. HCW Biologics also has collaboration and licensing arrangements with Wugen Inc. and WY Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HCWB
|
$5.28
|
32.3% Upside
|
Undervalued
|
$30
|
651.9% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-0.3x
|
0.8x
|
0.7x
|
4.571 M
|
5.284 M
|
59.0%
|
86.9%
|
-6.6
|
—
|
63.2%
|
